Tenderwize
Retour à la recherche

Open-house discount agreement for Levothyroxin-Natrium

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Levothyroxin-Natrium, ATC H03AA01

58/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

58 / 100

Complexité

54 / 100

Facteurs de risque

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive supply/discount agreement for Levothyroxin-Natrium, ATC H03AA01.
  • Open-house accession model with identical, pre-set contract terms for qualifying pharmaceutical companies.
Afficher le résumé complet

This is an open-house supply arrangement for pharmaceutical discount agreements on Levothyroxin-Natrium (ATC H03AA01) with AOK Bayern. It is not a competitive open procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract term starts earliest on 2026-05-01 and ends on 2028-04-30, with a final contract entry deadline of 2028-03-03 11:00. No estimated contract value is provided.

Risques

The buyer explicitly states that this is an open-house model and not a normal open procedure; standard procurement assu...

Contract documents must be submitted through the communication area in the DTVP portal, not through the offer area; mis...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability must be submitted.

Critères d'attribution

Lot 1

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house discount agreement for Levothyroxin-Natrium

Single lot covering non-exclusive open-house discount agreements for the pharmaceutical product Levothyroxin-Natrium (ATC H03AA01). The buyer indicates that contracts are identical, non-individually negotiable, and open to all interested pharmaceutical companies meeting the stated suitability requirement. Performance is in Germany, Bayern (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No lot-specific award criteria are stated; this appears to be an open-house accession model rather than a scored award process.

Date limite

Deadline Mar 03, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
180221-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30